13F Holdings
中文EN

PRE Prenetics Global Ltd IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1876431 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY40.8%
TTM net income YoY26.2%
TTM EPS YoY33.5%
Revenue 3-yr CAGR34.7%
Net income 3-yr CAGR—

Margins

Gross margin50.3%
Operating margin-157.2%
Net margin-151.2%
FCF margin-97.6%
EBITDA margin—

Returns

ROE-24.6%
ROA-19.8%
ROIC (approx.)-27.3%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets19.8%
Debt / equity0.00x
Current ratio2.36x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.62x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue3.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31
Income statement
Revenue$30.62M$21.74M$13.16M$12.53M$65.18M
Cost of revenue$15.22M$12.91M$9.55M$8.93M$38.83M
Gross profit$15.40M$8.83M$3.62M$3.60M$26.34M
R&D expense$10.92M$11.66M$5.99M$6.39M$2.78M
Operating income-$48.14M-$51.91M-$66.02M-$56.66M-$995,126
Interest expense——$4.20M$5.24M$59,567
Pretax income-$57.70M-$56.67M-$225.82M-$216.55M-$3.90M
Income tax-$7.87M-$269,000-$245,000$2.57M-$1.94M
Net income-$46.30M-$62.72M-$190.45M-$174.01M-$1.94M
EPS (basic)-3.71-5.58-37.57-178.81-0.15
EPS (diluted)-3.71-5.58-37.57-178.81-0.15
Weighted avg. shares (diluted)12.49M11.25M5.07M——
Balance sheet
Cash & equivalents$52.25M$45.71M$146.66M$35.29M$14.49M
Short-term investments$0$16.00M$19.92M——
Receivables$16.77M$17.66M$53.16M$54.86M—
Inventory$6.57M$3.13M$4.53M$6.83M—
Current assets$86.15M$93.66M$241.81M$106.89M—
PP&E, netmay include right-of-use assets (IFRS)$7.81M$5.78M$13.10M$13.04M—
Goodwill$37.36M$29.17M$33.80M$3.98M$3.99M
Intangibles$11.57M$13.43M$14.79M$23.83M—
Total assets$213.57M$254.17M$312.13M$148.51M—
Current liabilities$36.55M$39.48M$57.20M$58.74M—
Total liabilities$42.23M$44.01M$68.67M$549.40M—
Shareholders' equity$170.39M$206.36M$237.06M-$400.81M$31.01M
Shares outstanding12.98M12.21M———
Cash flow statement
Operating cash flow-$28.87M-$13.77M$14.52M$13.42M-$2.88M
Capital expenditure$1.01M$345,000$4.95M$8.55M$2.86M
Free cash flow-$29.88M-$14.11M$9.57M$4.87M-$5.74M
Investing cash flow$38.54M-$82.95M-$46.15M-$22.02M-$5.97M
Financing cash flow-$3.34M-$4.70M$143.32M$29.32M$11.84M
Stock-based compensation$7.85M$10.59M$31.58M$22.49M$1.62M

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.